Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -57.20% is 24% above its 5-year average of -75.08%, near the high end of its 5-year range (-117.72%–-55.54%).
16.01% above its 12-month average of -68.10%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.50%.
RETURN ON ASSETS (ROA)
-57.20%
RETURN ON ASSETS (ROA) AVG TTM
-68.10%
RETURN ON ASSETS (ROA) AVG 3Y
-82.79%
RETURN ON ASSETS (ROA) AVG 5Y
-75.08%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.01%
CURRENT VS 3Y AVG
+30.91%
CURRENT VS 5Y AVG
+23.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-22.62%
median of 373 covered companies
CURRENT VS SECTOR MEDIAN
-152.87%
vs the sector median at left
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$12.89B
Return on Assets (ROA)
2.01%
TTM Avg
3.05%
3Y Avg
3.16%
5Y Avg
3.84%
Market Cap
$13.19B
Return on Assets (ROA)
6.18%
TTM Avg
14.27%
3Y Avg
15.75%
5Y Avg
18.01%
Market Cap
$12.52B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
Market Cap
$12.49B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
Market Cap
$12.17B
Return on Assets (ROA)
4.91%
TTM Avg
1.34%
3Y Avg
-0.28%
5Y Avg
0.04%
Market Cap
$12.00B
Return on Assets (ROA)
8.33%
TTM Avg
7.48%
3Y Avg
6.38%
5Y Avg
5.99%
Market Cap
$14.16B
Return on Assets (ROA)
33.29%
TTM Avg
-24.43%
3Y Avg
-40.18%
5Y Avg
-39.80%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | -57.20% | -68.10% | -82.79% | -75.08% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 2.01% | 3.05% | 3.16% | 3.84% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 6.18% | 14.27% | 15.75% | 18.01% |
| Baxter International Inc. (BAX)vs › | $12.52B | -5.37% | -3.64% | -1.62% | 0.47% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 8.13% | 5.32% | 4.08% | 2.47% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 4.91% | 1.34% | -0.28% | 0.04% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 8.33% | 7.48% | 6.38% | 5.99% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 33.29% | -24.43% | -40.18% | -39.80% |
| DaVita Inc. (DVA)vs › | $11.47B | 4.79% | 4.84% | 4.27% | 4.56% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 7.03% | 4.83% | 6.67% | 7.46% |
ROA
-57.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -77.92% |
| 2024-12-31 | -58.28% |
| 2023-12-31 | -117.72% |
| 2022-12-31 | -77.23% |
| 2021-12-31 | -55.54% |
| 2020-12-31 | -63.78% |
| 2019-12-31 | -41.23% |
| 2018-12-31 | -28.12% |
| 2017-12-31 | -31.17% |
